Nexvet Biopharma public limited company (NASDAQ: NVET)
Nexvet Biopharma public limited company (NVET), a clinical stage biopharmaceutical company yesterday announced positive results from its NV-01 pivotal study. NV-01 is used for the treatment and therapy to control the pain of osteoarthritis in dogs. The study showed that the primary endpoints were met and NV-01 showed statistical improvement over the placebo.
Nexvet Biopharma public limited company CEO Comments
Dr. Mark Heffernan, Chief Executive Officer of Nexvet, commented:
“This is a tremendous outcome for Nexvet and we are particularly pleased to receive strong data supporting the long duration of efficacy following a single monthly injection, a key advantage for monoclonal antibody therapies over small molecules. This achievement is a testament to the power and potential of our proprietary PETization platform, invented by our Chief Scientific Officer Dr. David Gearing, to produce effective 100% species-specific veterinary therapeutic candidates,” commented. Globe Newswire
NVET Technical Analysis
NVET gapped up in price yesterday to $6.00, up from the prior day’s close of $4.88, which is a 23% increase on the favorable news. Taking a look at the daily chart, we can see the last time NVET traded above this price level was on September 9th, when it closed at $6.26. Taking a further look back on the chart we can see that NVET has been in an overall decline dating back to April 29th when it traded at $9.31. More recently, NVET has been rebounding off of lows of $3.69 reached on October 22nd. NVET does have a low float of 5.63 million shares and was trading over 4 times the normal daily trading volume. Both of these factors make the stock a prime candidate for the gap and go strategy. For trading purposes, my entry point would have been $6.10 looking for a run up to $6.50. My stop loss would have been $5.90, fearing anything below that and the stock would start to fill in the gap up.
Company Profile
Nexvet Biopharma public limited company, incorporated on August 14, 2014, is a clinical-stage biopharmaceutical company focusing on developing therapies for companion animals. The Company is engaged in developing and commercializing species-specific biologics based on human biologics. The Company’s PETization platform is an algorithmic approach that enables it to create monoclonal antibodies that are designed as self or native by an animal’s immune system. PETization is designed to build the data from clinically tested human therapies to create therapies for companion animals. The Company uses PETization to convert human and rodent monoclonal antibodies (mAbs) into species-specific canine, feline and equine mAbs. The Company’s products include NV-01, NV-02 and NV-08. NV-01 is a mAb for the control of pain associated with osteoarthritis in dogs. NV-02 is a mAb for the control of pain associated with degenerative joint disease in cats. NV-08 is a receptor fusion protein for the treatment of chronic inflammatory diseases, including atopic dermatitis, in dogs.
NV-01 is a PETized mAb that inhibits the activity of canine nerve growth factor (NGF) in dogs. Nexvet is developing NV-01 as a treatment to control pain associated with canine osteoarthritis.
NV-02 is a species-specific mAb targeting NGF, which is developed as a long-acting analgesic for chronic pain associated with degenerative joint disease, including osteoarthritis, in cats. NV-02 also reduces lameness scores in an acute feline model of inflammatory pain.
NV-08 is a fusion protein that is a tumor necrosis factor (TNF) inhibitor for canine inflammatory diseases. NV-08 links a canine antibody’s tail region, which binds to receptors to activate the immune system, with the extracellular domains of the canine TNF receptor. NV-08 acts in an analogous manner to the human therapeutic fusion protein, Enbrel, which binds and inhibits the activity of the inflammatory mediator TNF-a.
The Company competes with Aratana Therapeutics, Inc., Kindred Biosciences, Inc., Zoetis, Inc., Bayer AG, Boehringer Ingelheim GmbH, Eli Lilly and Company, Merck & Co., Inc. and Sanofi S.A. Reuters
